Genomics studies of AML in patients older than 60 years of age (ECOG-ACRIN Cancer Research Group's clinical trial e3999)
Acute Myeloid Leukemia (AML) is a disease of old age with a median diagnosis age of 69 years (SEER data 2024). Despite progress in our field, as patients age, they suffer from worse clinical outcomes compared to younger patients. A better understanding of disease biology is needed to yield discoveries that will contribute to the identification of therapeutic vulnerabilities in this aged population, and in the long-term, result in improved survival rates. Although AML patients older than 60 are most of the patients diagnosed with this disease, few studies have solely focused on the molecular features of this disease in the aged population. This study aimed to discover the molecular features of AML patients older than 60 years of age. De-identified blood and bone marrow specimens... (for more see dbGaP study page.)